Information  X 
Enter a valid email address

XL TechGroup, Inc. (XLT)

  Print   

Tuesday 18 April, 2006

XL TechGroup, Inc.

TyraTech Mexico agreement

XL TechGroup, Inc.
18 April 2006


Press Release                                                      18 April 2006


                               XL TechGroup, Inc.


                       ('XL TechGroup' or 'the Company')


                    TyraTech, an XL TechGroup company, signs

                  supply and distribution agreement for Mexico


XL TechGroup, Inc. (AIM: XLT), the systematic architect and builder of an
ongoing stream of high value new companies, announces that its company TyraTech
LLC has signed an exclusive supply and distribution agreement with Mexican
company Terra Quest SA de CV which has excellent relationships with key
governmental and commercial partners in Mexico.  They will represent TyraTech's
products for insect, vector and parasite control within Mexico.


The initial Mexico agreement is for five years and includes specific sales
milestones.  This agreement is designed to provide immediate access to local
governmental and commercial opportunities.  Terra Quest has made quick progress,
already executing a successful test at one of the leading hospitals in Mexico,
the Universitario De Nuevo Leon part of the Medicine Faculty of the 'Autonomous
University of Nuevo Leon' in Monterrey.  This has produced a small initial order
which TyraTech is confident will lead to larger follow-on orders.


In addition, a test of TyraTech's mosquito larvacide with the Mexican Department
of Health (Vectors Division) is scheduled for May 2006.  This test is designed
to determine how the technology can best be utilized to provide a safe
alternative to current synthetic chemicals used to control mosquito populations
in wide areas including lakes and ponds that are key breeding grounds for
mosquitoes.  These current chemical based solutions raise significant issues
related to safety for aquatic life, impact on drinking water and general
exposure of the Mexican population to insecticides that may cause negative
health affects.


TyraTech has a unique biotechnology which has been applied to the creation of an
entirely new class of natural insecticides that trials are demonstrating to be
both safe and highly effective.  The core technology, which utilises the
successful reproduction of chemo receptors in a stable cell line to identify
highly effective essential oil compounds, has a wide variety of applications in
human health care (e.g., mosquito vector control, head lice, parasitic control
etc.) as well as in institutions that serve health sensitive populations such as
hospitals, schools and day care centres.  The active ingredients are based on
natural plant oils which are environmentally-friendly and designed to be
entirely safe for both humans and animals.


Dr. Jaime Herrera Melendez, the Technical Secretary of the hospital in Monterrey
said: 'We strive for providing the best possible environment for our patients
and staff.  The success of the test of the TyraTech natural insecticide in our
hospital opens up the opportunity to replace synthetic chemicals with a product
we can all feel good about.'


Dr John Scott, CEO of XL TechGroup, said:  'This agreement is an exciting
development as it represents TyraTech's initial entry point into the potentially
very large markets for wide area mosquito and parasite control within developing
countries.  The approval of the test results by this leading hospital in Mexico
has a high referral value given its status as a highly respected, significant
research facility.  We expect this initial agreement to be just the first in
Central and South America, as well as in other countries such as Thailand where
an initial letter of understanding has been agreed with a potential 
distributor.'


                                    - ends -



For further information:
XL TechGroup Inc.
John Scott / Harold Gubnitsky                               Tel: +1 321 409 7403
[email protected]                                          www.xltechgroup.com



XL TechGroup media inquiries:
Abchurch Communications
Heather Salmond / Chris Munden                         Tel: +44 (0) 20 7398 7700
[email protected]                        www.abchurch-group.com



NOTES TO EDITORS


About XL TechGroup

XL TechGroup identifies unmet market needs in the Biotech, Ecotech and Medtech
sectors and then systematically creates and develops successful disruptive
technology businesses to exploit these needs.  The Company has developed a
unique proven method to rapidly bring companies from inception to liquidity,
matching unexploited IP from a group of corporate and technology partners to the
identified unmet market need.  XL TechGroup employs its own predictive algorithm
to ensure the market will rapidly adopt the identified solution and then moves
to scale the company specifically created to exploit the opportunity.


Before forming XL TechGroup, the management team created substantial value for
shareholders over a twelve year period, successfully exiting six technology
businesses at an average market valuation of approximately US$500 million.


The listing of the first company created under the XL TechGroup banner, AgCert
International, continues to validate the systematic approach to value creation.


•         AgCert International was created by XL TechGroup in May 2002 and is a
global leader in the production and sale of agriculturally derived greenhouse
gas emission reductions, with business in Europe, Asia, North America and South
America.  AgCert was listed on the London Stock Exchange in June 2005 and XL
TechGroup maintains a 27.2% interest in AgCert.  www.agcert.com


The second and third companies in the new generation of XL TechGroup businesses
are:


•         TyraTech LLC, which was created by XL TechGroup in July 2004, is
developing a new class of insecticides utilizing all natural active ingredients.
  TyraTech is able to quickly evaluate natural ingredient combinations by
utilizing a patent-pending high throughput chemoreceptor screening process that
accurately predicts effectiveness levels.  TyraTech's development is progressing
rapidly in both insecticidal and related human healthcare applications.
TyraTech, which is 66.7% owned by XL TechGroup, is continuing discussions with
companies in North America, Asia and Europe as well as numerous national public
health programs about the licensing and distribution rights for its
patent-pending  formulations in relation to natural insecticide and personal
care products.  www.tyratech.com


•         DxTech LLC was created by XL TechGroup in July 2005, and is developing
a unique micro-fluidic platform that replaces essentially all biological tests
currently performed at reference laboratories with a fully-automated,
point-of-need device.  This technology has applications in significantly
lowering costs and increasing efficiency for major pharmaceutical companies in
their clinical trials, the provision of diagnostics in developing countries and
delivering a new revenue stream for doctors in the USA.  DxTech is 88% owned by
XL TechGroup.  www.dxtech.com


XL TechGroup has a number of other opportunities already at an advanced stage in
its business creation pipeline, and expects to create one-to-two new companies
annually that can each achieve a liquidity event worth at least US$400 million
within four years from inception.

For further information, see www.xltechgroup.com


                      This information is provided by RNS
            The company news service from the London Stock Exchange                                                                                                                         

a d v e r t i s e m e n t